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Wlds-Mediated Protection of Dopaminergic
Fibers in an Animal Model of Parkinson Disease
Wlds mice express a fusion protein linking the nicotin-
amide mononucleotide adenylyl transferase enzyme
with the terminal portion of the ubiquitination factor E4b
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Swiss Federal Institute of [6]. This molecule, resulting from an 85 kb tandem tripli-
cation, delays the self-destruction program of tran-Technology Lausanne, EPFL
Lausanne sected axons, a process called Wallerian degeneration.
Similarly, Wlds prevents the retrograde axonal degenera-Switzerland
tion of motoneurons in the pmn/pmn mouse model, ex-
tending the life span of these animals [9]. In the present
study, the effect of the Wlds mutation was evaluatedSummary
in an animal model of PD. By performing stereotaxic
injections of 6-hydroxydopamine (6-OHDA) in the nigro-Parkinson disease (PD) is characterized by the pro-
gressive degeneration of substantia nigra dopaminer- striatal pathway of Wlds mice, we examined whether
dopaminergic axons could be transiently preserved fol-gic neurons projecting to the striatum. Since the deficit
in striatal dopamine is the main cause of PD symp- lowing injury induced by oxidative stress.
The presence of the Wlds protein in dopaminergic neu-toms, it appears critical to preserve axon terminals
[1]. Significant axon protection from peripheral nerve rons of the SNpc was confirmed by double immunostain-
ing for TH and Wlds proteins (Figure 1). In Wlds mice,Wallerian degeneration is observed in Wlds mice [2–5],
a phenotype conferred by a spontaneous dominant most of the cells expressing the TH dopaminergic
marker were found to be positive for the Wlds protein,mutation [6]. To assess any Wlds-mediated rescue of
dopamine fibers in a PD model, the nigrostriatal path- essentially present within the nucleus. This nuclear pat-
tern of Wlds expression was previously reported in otherway of Wlds mice was lesioned with 6-hydroxydopa-
mine (6-OHDA), a catecholaminergic neurotoxin [7]. neuronal subpopulations [10].
Eleven days after injection of 6-OHDA in the rightFollowing 6-OHDA injection in the medial forebrain
bundle, Wlds mice showed remarkable dopamine fiber medial forebrain bundle (MFB), immunostaining for two
dopaminergic-specific markers (TH and DAT) was per-protection in the striatum. Drug-induced rotational
behavior confirmed the nigrostriatal fiber ability to formed to compare the extent of the striatal lesion be-
tween Wlds and control mice (Figure 2). Surviving dopa-release dopamine, although revealing an abnormal
neurotransmitter control presumably due to disrupted minergic fibers in the striatum were quantified by optical
densitometry of TH and DAT immunoreactivity. As ex-axonal transport. Following 6-OHDA injection in the
midstriatum, only a protection trend was observed. pected, injection of 6-OHDA in control mice resulted in
rapid and extensive dopaminergic denervation in theStrikingly, no protection of Wlds nigral dopaminergic
cell bodies was obtained following either nigrostriatal lesioned striatum, with 7.2%  1.2% TH and 3.8% 
0.6% DAT remaining optical density compared to thelesion. Besides showing subtle differences in the de-
generation process between subcellular compart- nonlesioned side. Remarkably, strong protection of the
dopaminergic fibers in the striatum was observed inments, the reported Wlds-mediated protection of the
dopamine axon terminals in an animal model of PD Wlds mice, with 26.9%  2.3% TH and 26.1%  3.3%
DAT optical density, showing a highly significant differ-may lead to the understanding of mechanisms under-
lying axon loss and to the development of new thera- ence with respect to the control group (p  0.001 for
both markers).peutic approaches.
To determine whether the observed dopaminergic
axon protection in the striatum of Wlds mice is depen-Results and Discussion
dent on the site of 6-OHDA injection, a second experi-
ment was performed by injecting the toxin in the rightParkinson disease (PD) is a common neurodegenerative
midstriatum. Twelve days following 6-OHDA injectionsdisorder characterized by the progressive loss of dopa-
at the level of dopaminergic nerve terminals, as opposedminergic neurons in the substantia nigra pars compacta.
to the MFB level, only a protection trend was observed(SNpc). The resulting failure of the nigrostriatal pathway
in Wlds mice (26.4% 5.7% TH and 33.1% 6.3% DATleads to profound dopamine deficiency, causing brady-
optical density compared to 18.0% 5.6% and 20.8%kinesia, tremor, and rigidity.
7.5%, respectively, in the control mice, revealing noThe preservation of long neuronal processes appears
significant difference between both groups).to be essential in the development of protective or re-
Injection into the MFB reproduces some features ofgenerative strategies for the treatment of PD [1]. Recent
late-stage PD with extensive denervation and loss ofobservations indicate that axonal self-destruction oc-
dopaminergic neurons. In contrast, injection at the levelcurs by active mechanisms distinct from apoptosis [8].
of striatal nerve terminals is characterized by a pro-
gressive degeneration leading to a partial loss of dopa-
*Correspondence: patrick.aebischer@epfl.ch
minergic neurons over several weeks [11]. The important1These authors contributed equally to this work.
difference observed between these two models in the2Present address: Waisman Center, UW-Madison, 1500 Highland
Avenue, Madison, Wisconsin. axonal protection conferred by the Wlds protein sug-
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on the axon segments distal to the site of toxin injection.
This axon part may undergo a self-destruction process
similar to Wallerian degeneration, presumably triggered
by the disruption of axonal transport due to 6-OHDA-
mediated damage to the neuronal cytoskeleton. Simi-
larly, protection of neuromuscular junctions following
peripheral axotomy is dependent on the site of the nerve
lesion in Wlds mice [12].
To assess any protective effect of the Wlds protein on
the cell soma, nigral TH-positive neurons were quanti-
fied following 6-OHDA injections in the MFB (close to
the SN) and striatum (distant to the SN). Following MFB
injection, Wlds mice had 35.3% 3.9% loss of TH-posi-
tive neurons on the lesioned side compared to 35.7%
7.9% in the controls (Figure 3A). In the intrastriatal
model, Wlds mice had 27.8% 5.3% loss of TH-positive
neurons compared to 25.2%  5.1% in the controls
(Figure 3B). No significant effect of the Wlds protein
could be demonstrated. While the expression of the Wlds
protein delays the loss of the axon segment distal to
6-OHDA exposures, it does not prevent the retrograde
process of dying back ultimately leading to the death
of the cell bodies. This subcellular specificity of the Wlds-
mediated protection highlights a subtle compartmental-
ization of the degeneration process. Disparities between
the axon and cell body in response to neuroprotective
treatments have already been demonstrated both in
vitro and in vivo. While the expression of bcl-2 prevents
Figure 1. Double TH and Wlds Immunostaining the death of neuronal cells, it has no effect on axon
loss, either following transection [13] or in the pmn/(A) Lower magnification of Wlds staining (green label) and TH staining
(red label) in the SNpc of Wlds mice. pmn mouse model [14]. In these mice, a similar effect
(B) Higher magnification of (A), showing a predominant nuclear local- is obtained in response to glial cell line-derived neuro-
ization of the Wlds fusion protein. trophic factor (GDNF) [15]. The axonal program of self-
(C) Same procedure in the SNpc of control mice, revealing an ab-
destruction does not depend on caspases, the cysteinesence of Wlds staining.
proteases involved in cell apoptosis [16]. In the 6-OHDAScale bar for (A), 100 m; scale bar for (B) and (C), 25 m.
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
models of PD, inhibitors of caspases protected the
gests that various mechanisms of degeneration can oc- somata from cell death induced by oxidative stress,
cur along dopaminergic axons in response to 6-OHDA without any effect on dopaminergic terminals [17, 18].
Complementary approaches appear to be promising ininsults. A clear protective effect of Wlds is observed only
Figure 2. TH and DAT Expression in the Striatum of Wlds and Control Mice 11 Days after Injection of 6-OHDA in the MFB
(A) Mean TH and DAT striatal optical densities on the lesioned side expressed as percentage of the contralateral values. Significant difference
of optical density is obtained between Wlds and control mice for both dopaminergic markers (***p  0.001), revealing clear Wlds-mediated
dopamine fiber protection in the striatum.
(B) DAT immunostaining in mice striatum showing a striking preservation of the dopamine fibers in Wlds mice as compared to the controls.
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Figure 3. Quantification of TH-Positive Neurons in the SNpc of Wlds and Control Mice
(A) Percentage of loss of TH-positive neurons 11 days after injection of 6-OHDA in the MFB of Wlds and control mice. TH immunostaining at
the SN level showed a similar pattern of lesion in both Wlds and control mice.
(B) Percentage of loss of TH-positive neurons 12 days after injection of 6-OHDA in the striatum of Wlds and control mice. TH immunostaining
at the SN level showed a similar pattern of lesion in both Wlds and control mice. In either experiment, no significant protection of the cell
soma was observed between Wlds and control mice. Scale bar, 500 m.
the development of protective and restorative treat- pamine will be rapidly released within the synaptic cleft
via reverse action of the DAT transporter [19, 20]. In thements for the whole neuronal function. For instance, a
synergistic effect was obtained using a combination of intact side, most of the dopamine is sequestrated within
presynaptic vesicles and thus has to be translocated toX chromosome-linked inhibitor of apoptosis (XIAP) and
GDNF, rescuing both dopaminergic neurons and their the cytoplasm, however, at a slower limiting rate, before
being released [21]. This abnormal storage of dopamineterminals [17].
Unexpected effects on drug-induced turning behavior in the preserved fibers may result from a defective vesic-
ular sequestration due to disrupted anterograde axonalwere observed in mice showing distal protection of their
dopaminergic fibers. Axon protection was associated transport of presynaptic vesicles at the lesion site. In
addition, these elevated concentrations of cytoplasmicwith striking drug-induced rotational behavior 7 days
after the MFB lesion in Wlds mice, consisting of extensive dopamine increase the neurotransmitter gradient across
the plasma membrane [20], inducing spontaneous do-contralateral turning in response to amphetamine (1039
224 contralateral turns/90 min versus 406 83 ipsilateral pamine release and leading to the observed postsynap-
tic desensitization. The observed behavior of Wlds miceturns in control mice; p  0.001) and modest ipsilat-
eral turning in response to apomorphine (106  16 ipsi- lesioned in the MFB suggests a functional preservation
of dopamine synthesis in the spared axons. However,lateral turns/60 min versus 12  29 ipsilateral turns in
control mice; p  0.01) (Figure 4). The capacity of pre- the disconnection of these axons from the cell body
leads to nonphysiological mechanisms of neurotrans-served axons to synthesize dopamine certainly ac-
counts for the loss of amphetamine-induced ipsilateral mitter release and sequestration.
Although the etiology of sporadic PD is still unclear,rotations measured in the Wlds animals. However, it does
not explain the observed reversal of the turning behavior several mechanisms have been proposed to participate
in the progressive degeneration of the nigrostriatal path-when compared to lesioned control mice. Moreover,
apomorphine administration resulted in slight ipsilateral way. With the recent discovery of mutations in the -synu-
clein gene involved in familial forms of the disease [22],rotations, suggesting postsynaptic desensitization in
the lesioned side of Wlds mice. These unexpected rota- several questions have been raised about the role of
this molecule in PD pathogenesis. Although the exacttional behaviors may reveal an abnormal accumulation
of nonvesicular dopamine within preserved axon termi- sequence of neurodegenerative events is not known, it
has been proposed that misfolding of -synuclein, localnals. In response to amphetamine, this cytoplasmic do-
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parkin gene, an E3 ubiquitin ligase, and the UCH-L1
gene, a ubiquitin C-terminal hydrolase, have been asso-
ciated with familial forms of this disease [26–28]. Like-
wise, an in-frame deletion in UCH-L1 leads to the pro-
gressive dying back of axons in the mouse model of
gracile axonal dystrophy (gad) [29]. These similarities
suggest that defects in the regulation of protein turnover
may underlie some pathogenic mechanisms of axonal
degeneration. Addressing these issues may provide a
better understanding of the various processes of neuro-
degeneration involved in PD and contribute to the elabo-
ration of therapeutic approaches to preserve the dopa-
minergic function.
Supplemental Data
Supplemental data including the experimental procedures are avail-
able at http://www.current-biology.com/cgi/content/full/14/4/326/
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